Health Care & Life Sciences » Biotechnology | Palatin Technologies Inc.

Palatin Technologies Inc.

Palatin Technologies Inc.
Stock Exchange NYSE
EPS
$0.02
Market Cap
$222.02 M
Shares Outstanding
215.56 M
Public Float
191.81 M
Palatin Technologies Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
198.68 M
Public Float
196.67 M

Profile

Address
Cedar Brook Corporate Center
Cranbury New Jersey 08512
United States
Employees -
Website http://www.palatin.com
Updated 07/08/2019
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress.

Financials

View All
Created with Highcharts 5.0.14Palatin Technologies Inc.Net Income. Fiscal year is July-June. All values USD Thousands.20 86220 86213 92813 92817 66517 66551 71251 71213 33113 33124 70224 702201320142015201620172018010k20k30k40k50k60k
Created with Highcharts 5.0.14Palatin Technologies Inc.Sales/Revenue. Fiscal year is July-June. All values USD Thousands.10100012 95112 9510044 72344 72367 13467 134201320142015201620172018020k40k60k80k

Carl Spana
President, Chief Executive Officer & Director
John K. A. Prendergast
Chairman